Morgan Stanley’s Cadrenal Therapeutics CVKD Stock Holding History

Morgan Stanley’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$760	Sell	704 -2	-0.3%	-$4	﹤0.01%	7562
2026 Q2	$2.36K	Buy	706 +606	+606%	+$2.88K	﹤0.01%	7374
2026 Q1	$512	Sell	100 -980	-91%	-$6.87K	﹤0.01%	7612
2025 Q4	$7.32K	Buy	1,080 +200	+23%	+$2.26K	﹤0.01%	6963
2025 Q3	$12.2K	Buy	880 +450	+105%	+$5.57K	﹤0.01%	6845
2025 Q2	$5.18K	Sell	430 -700	-62%	-$10.4K	﹤0.01%	7024
2025 Q1	$19.9K	Sell	1,130 -16	-1%	-$294	﹤0.01%	6572
2024 Q4	$16.6K	Buy	+1,146	New	+$16.6K	﹤0.01%	6628

Other funds holding CVKD

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Morgan Stanley's CVKD Position: Q3 2026 in Review

Morgan Stanley reduced its Cadrenal Therapeutics (CVKD) stake by 0.28% in Q3 2026, selling an estimated $4 and leaving 704 shares worth $760. The position accounts for ﹤0.01% of the portfolio, ranked #7562.

Morgan Stanley first reported a position in CVKD in Q4 2024 and has held it in 8 quarters since. The position peaked at $19.9K in Q1 2025. 23 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

Morgan Stanley held 704 shares of Cadrenal Therapeutics worth $760 as of Q3 2026.
Morgan Stanley sold 2 Cadrenal Therapeutics shares in Q3 2026, an estimated $4.
Cadrenal Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #7562 holding.
Morgan Stanley first reported a position in Cadrenal Therapeutics in Q4 2024 and has held it in 8 quarters since.
Morgan Stanley's Cadrenal Therapeutics position peaked at $19.9K in Q1 2025.
23 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.